Levosimendán Sala

Levosimendan, the active ingredient in Levosimendán Sala, is a calcium sensitizer / inodilator presented as a solution for injection for intravenous use. It treats acute decompensated heart failure in hospitalized patients by improving cardiac contractility and reducing vascular resistance, thereby enhancing cardiac output and relieving symptoms of congestion.

GNH USA supplies Levosimendán Sala as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Levosimendan is used in the management of acute decompensated heart failure, a condition characterized by sudden worsening of cardiac function. - Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion. - Severe chronic heart failure (as adjunctive therapy): provides hemodynamic support when standard treatments are insufficient. - Peri‑operative cardiac support in high‑risk cardiac surgery: stabilises haemodynamics during and after the procedure.

Levosimendan may be associated with several adverse reactions.

Common Side Effects: - Hypotension: reduction in blood pressure, especially after loading dose. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Dizziness: feeling of light‑headedness. - Arrhythmias: premature beats or mild rhythm disturbances.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring intervention. - Ventricular arrhythmias: potentially life‑threatening rhythm disorders. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Pulmonary edema: fluid accumulation in lungs. - Anaphylactic reaction: rare allergic response. - Liver enzyme elevation: significant increase in transaminases.

Levosimendan requires careful monitoring and specific safety measures. - Blood pressure monitoring: check regularly to detect hypotension. - Cardiac rhythm observation: continuous ECG to identify arrhythmias. - Contraindication in severe hypotension: avoid use when systolic pressure is <90 mmHg. - Caution in renal or hepatic impairment: dose adjustment may be needed. - Interaction with other vasodilators: assess risk of additive blood‑pressure effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase levosimendan plasma levels. - Strong CYP2D6 inhibitors (e.g., quinidine, paroxetine): can elevate active metabolite concentrations. - Concurrent potent vasodilators (e.g., nitroglycerin, hydralazine): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate volume depletion and hypotension. - ACE inhibitors or ARBs: additive blood‑pressure lowering effect. - Beta‑blockers: may blunt desired inotropic response. - Anti‑arrhythmic agents: monitor for rhythm changes. - Anticoagulants: observe for bleeding if hypotension occurs.